


What is Claimed:

1. A library of compounds having a structure corresponding to that shown in Formula I, below, or a pharmaceutically acceptable salt thereof:



wherein:

X is O or NH;

R<sup>1</sup> is selected from the group consisting of a hydrido, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> substituted alkyl, C<sub>7</sub>-C<sub>16</sub> phenylalkyl, C<sub>7</sub>-C<sub>16</sub> substituted phenylalkyl, phenyl, substituted phenyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, and a C<sub>3</sub>-C<sub>7</sub> substituted cycloalkyl group;

R<sup>2</sup> is selected from the group consisting of a C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> substituted alkyl, C<sub>7</sub>-C<sub>16</sub> phenylalkyl, C<sub>7</sub>-C<sub>16</sub> substituted phenylalkyl, phenyl, substituted phenyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>7</sub> substituted cycloalkyl, and a C<sub>3</sub>-C<sub>7</sub> substituted cycloalkyl group; and

R<sup>3</sup> is selected from the group consisting of a hydrido, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> substituted alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> substituted alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>2</sub>-C<sub>10</sub> substituted alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>7</sub> substituted cycloalkyl, phenyl, C<sub>7</sub>-C<sub>16</sub> phenylalkyl, C<sub>7</sub>-C<sub>16</sub> phenylalkenyl, C<sub>7</sub>-C<sub>16</sub> phenylalkynyl and a C<sub>7</sub>-C<sub>16</sub> substituted phenylalkenyl group.

2. The library according to claim 1 wherein R<sup>1</sup> is selected from the group consisting of a hydrido, methyl, benzyl, 2-butyl, N,N-dimethylaminobutyl, N-methylaminobutyl, N-methyl-N-benzylaminobutyl, 2-methylpropyl, methylsulfinylethyl, methylthioethyl, N,N-dimethylaminoethyl, N,N-dimethylaminopropyl, N',N',N'-trimethylguanidinopropyl, N',N',N'-tribenzyl-guanidinopropyl, N',N'-dibenzylguanidinopropyl, N'-methylguanidinopropyl, hydroxymethyl, 1-hydroxyethyl, 2-propyl, N-methyl-3-indolylmethyl, 4-methoxybenzyl, 4-hydroxybenzyl, propyl, butyl, cyclohexylmethyl, phenyl, 2-naphthylmethyl, and a 4-imidazolylmethyl substituent.


3. The library according to claim 1 wherein R<sup>2</sup> is selected from the group consisting of a methyl, ethyl, isopropyl, n-propyl, butyl, t-butyl, cyclohexyl, n-octadecyl, phenyl, benzyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 3-chloro-4-methylphenyl, 3-bromo-4-methylphenyl, 3-fluorosulfonyl-phenyl, 3,4-(methylenedioxy)phenyl, 4-phenoxyphenyl, trans-2-phenylcyclopropyl, 4-toluenesulfonyl, 2-tolyl, 3-tolyl, 4-tolyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl,  $\alpha,\alpha,\alpha$ -trifluoro-2-tolyl,  $\alpha,\alpha,\alpha$ -trifluoro-3-tolyl,  $\alpha,\alpha,\alpha$ -trifluoro-4-tolyl, 2,5-dimethylphenyl, 3,4-dimethylphenyl and a 3,5-dimethylphenyl substituent.

4. The library according to claim 1 wherein R<sup>3</sup> is selected from the group consisting of a


hydrido, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, benzyl, and a substituted benzyl substituent.

5. The library according to claim 1 wherein the R<sup>1</sup> substituent is a side chain of an amino acid selected from the group consisting of Ala, Phe, Gly, Asp, Asn, Glu, Gln, His, Ile, Lys, Leu, Met, Arg, Nva, Ser, Thr, Val, Trp, Tyr, Nle, Cha, Chg, Fph, Cph, Nph, Aib, Abu, ala, phe, asp, asn, glu, gln, his, ile, lys, leu, met, arg, ser, thr, val, trp, tyr, nle, nva, cha, chg, fph, cph, aib, and abu wherein amino acids written with an initial capital letter are L-amino acids and those written in all lower case letters are D-amino acids.

6. The library of compounds according to claim 1 wherein said compounds have a structure corresponding to that shown in Formulas IIA or IIB below, or a pharmaceutically acceptable salt thereof:



7. A library of compounds having a structure corresponding to that shown in Formulas IIA or IIB, below, or a pharmaceutically acceptable salt thereof:



X is O or NH;

R<sup>2</sup> is selected from the group consisting of a methyl, ethyl, isopropyl, n-propyl, butyl, t-butyl, cyclohexyl, n-octadecyl, phenyl, benzyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 3-chloro-4-methylphenyl, 3-bromo-4-methylphenyl, 3-fluorosulfonyl-phenyl, 3,4-(methylenedioxy)phenyl, 4-phenoxyphenyl, trans-2-phenylcyclopropyl, 4-toluenesulfonyl, 2-tolyl, 3-tolyl, 4-tolyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, α,α,α-trifluoro-2-tolyl, α,α,α-trifluoro-3-tolyl, α,α,α-trifluoro-4-tolyl, 2,5-dimethylphenyl, 3,4-

dimethylphenyl and a 3,5-dimethylphenyl substituent;  
and


$R^3$  is selected from the group consisting of a hydrido,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl, benzyl, and a substituted benzyl group.

8. The library according to claim 7 wherein the  $R^1$  substituent is a side chain of an amino acid selected from the group consisting of Ala, Phe, Gly, Asp, Asn, Glu, Gln, His, Ile, Lys, Leu, Met, Arg, Nva, Ser, Thr, Val, Trp, Tyr, Nle, Cha, Chg, Fph, Cph, Nph, Aib, Abu, ala, phe, asp, asn, glu, gln, his, ile, lys, leu, met, arg, ser, thr, val, trp, tyr, nle, nva, cha, chg, fph, cph, aib, and abu wherein amino acids written with an initial capital letter are L-amino acids and those written in all lower case letters are D-amino acids.

9. The library according to claim 7 wherein the  $R^2$  substituent is selected from the group consisting of a phenyl, 4-halophenyl, 4-( $C_1$ - $C_6$ -alkyl)phenyl and a  $C_1$ - $C_6$  alkyl group.

10. The library according to claim 7 wherein the  $R^3$  substituent is selected from the group consisting of a hydrido, methyl, benzyl, 2-, 3- and 4-methylbenzyl, 2-, 3- and 4-fluorobenzyl, 2-, 3- and 4-chlorobenzyl, 2,4-, 3,4-, 3,5- and 2,6-difluorobenzyl, 4-(trifluoromethyl)benzyl, 4-(trifluoromethoxy)benzyl, 2-, 3-, and 4-methoxybenzyl, 3,5- and 3,4-dimethoxybenzyl, 2-, 3- and 4-nitrobenzyl, 2-, 3- and a 4-phenylbenzyl substituent.

11/5 A compound having a structure corresponding to that shown in Formula I, below, or a pharmaceutically acceptable salt thereof:



wherein:

X is O or NH;

R<sup>1</sup> is selected from the group consisting of a hydrido, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> substituted alkyl, C<sub>7</sub>-C<sub>16</sub> phenylalkyl, C<sub>7</sub>-C<sub>16</sub> substituted phenylalkyl, phenyl, substituted phenyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, and a C<sub>3</sub>-C<sub>7</sub> substituted cycloalkyl group;

R<sup>2</sup> is selected from the group consisting of a C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> substituted alkyl, C<sub>7</sub>-C<sub>16</sub> phenylalkyl, C<sub>7</sub>-C<sub>16</sub> substituted phenylalkyl, phenyl, substituted phenyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>7</sub> substituted cycloalkyl, and a C<sub>3</sub>-C<sub>7</sub> substituted cycloalkyl group; and

R<sup>3</sup> is selected from the group consisting of a hydrido, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> substituted alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> substituted alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>2</sub>-C<sub>10</sub> substituted alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>7</sub> substituted cycloalkyl, phenyl, C<sub>7</sub>-C<sub>16</sub> phenylalkyl, C<sub>7</sub>-C<sub>16</sub> phenylalkenyl, C<sub>7</sub>-C<sub>16</sub> phenylalkenyl and a C<sub>7</sub>-C<sub>16</sub> substituted phenylalkenyl group.


12. The compound according to claim 11 wherein R<sup>1</sup> is selected from the group consisting of a hydrido, methyl, benzyl, 2-butyl, N,N-dimethylaminobutyl, N-methylaminobutyl, N-methyl-N-benzylaminobutyl, 2-methylpropyl, methylsulfinylethyl, methylthioethyl, N,N-dimethylaminoethyl, N,N-dimethylaminopropyl, N',N',N'-trimethylguanidinopropyl, N',N',N'-tribenzyl-guanidinopropyl, N',N'-dibenzylguanidinopropyl, N'-methylguanidinopropyl, hydroxymethyl, 1-hydroxyethyl, 2-propyl, N-methyl-3-indolylmethyl, 4-methoxybenzyl, 4-hydroxybenzyl, propyl, butyl, cyclohexylmethyl, phenyl, 2-naphthylmethyl, and a 4-imidazolylmethyl substituent.

13. The compound according to claim 11 wherein R<sup>2</sup> is selected from the group consisting of a methyl, ethyl, isopropyl, n-propyl, butyl, t-butyl, cyclohexyl, n-octadecyl, phenyl, benzyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 3-chloro-4-methylphenyl, 3-bromo-4-methylphenyl, 3-fluorosulfonyl-phenyl, 3,4-(methylenedioxy)phenyl, 4-phenoxyphenyl, trans-2-phenylcyclopropyl, 4-toluenesulfonyl, 2-tolyl, 3-tolyl, 4-tolyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl,  $\alpha,\alpha,\alpha$ -trifluoro-2-tolyl,  $\alpha,\alpha,\alpha$ -trifluoro-3-tolyl,  $\alpha,\alpha,\alpha$ -trifluoro-4-tolyl, 2,5-dimethylphenyl, 3,4-dimethylphenyl and a 3,5-dimethylphenyl substituent.


14. The compound according to claim 11 wherein R<sup>3</sup> is selected from the group consisting of a hydrido, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, benzyl, and a substituted benzyl substituent.

15. The compound according to claim 11 wherein the R<sup>1</sup> substituent is a side chain of an amino acid selected from the group consisting of Ala, Phe, Gly, Asp, Asn, Glu, Gln, His, Ile, Lys, Leu, Met, Arg, Nva, Ser, Thr, Val, Trp, Tyr, Nle, Cha, Chg, Fph, Cph, Nph, Aib, Abu, ala, phe, asp, asn, glu, gln, his, ile, lys, leu, met, arg, ser, thr, val, trp, tyr, nle, nva, cha, chg, fph, cph, aib, and abu wherein amino acids written with an initial capital letter are L-amino acids and those written in all lower case letters are D-amino acids.

16. The compound according to claim 11 wherein said compounds have a structure corresponding to that shown in Formulas IIA or IIB below, or a pharmaceutically acceptable salt thereof:



17. A compound having a structure corresponding to that shown in Formulas IIA or IIB, below, or a pharmaceutically acceptable salt thereof:



wherein:



X is O or NH;

R<sup>1</sup> is selected from the group consisting of a hydrido, methyl, benzyl, 2-butyl, N,N-dimethylaminobutyl, N-methylaminobutyl, N-methyl-N-benzylaminobutyl, 2-methylpropyl, methylsulfinylethyl, methylthioethyl, N,N-dimethylaminoethyl, N,N-dimethylaminopropyl, N',N',N'-trimethylguanidinopropyl, N',N',N'-tribenzyl-guanidinopropyl, N',N'-dibenzylguanidinopropyl, N'-methylguanidinopropyl, hydroxymethyl, 1-hydroxyethyl, 2-propyl, N-methyl-3-indolylmethyl, 4-methoxybenzyl, 4-hydroxybenzyl, propyl, butyl, cyclohexylmethyl, phenyl, 2-naphthylmethyl, and a 4-imidazolylmethyl substituent;

R<sup>2</sup> is selected from the group consisting of a methyl, ethyl, isopropyl, n-propyl, butyl, t-butyl, cyclohexyl, n-octadecyl, phenyl, benzyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 3-chloro-4-methylphenyl, 3-bromo-4-methylphenyl, 3-fluorosulfonyl-phenyl, 3,4-(methylenedioxy)phenyl, 4-phenoxyphenyl, trans-2-phenylcyclopropyl, 4-toluenesulfonyl, 2-tolyl, 3-tolyl, 4-tolyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl,  $\alpha,\alpha,\alpha$ -trifluoro-2-tolyl,  $\alpha,\alpha,\alpha$ -trifluoro-3-tolyl,  $\alpha,\alpha,\alpha$ -trifluoro-4-tolyl, 2,5-dimethylphenyl, 3,4-dimethylphenyl and a 3,5-dimethylphenyl substituent; and

R<sup>3</sup> is selected from the group consisting of a hydrido, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, benzyl, and a substituted benzyl substituent.

18. The compound according to claim 17 wherein the R<sup>1</sup> substituent is a side chain of an amino acid selected from the group consisting of Ala, Phe, Gly, Asp, Asn, Glu, Gln, His, Ile, Lys, Leu, Met, Arg, Nva, Ser, Thr, Val, Trp, Tyr, Nle, Cha, Chg, Fph, Cph, Nph, Aib, Abu, ala, phe, asp, asn, glu, gln, his, ile, lys, leu, met, arg, ser, thr, val, trp, tyr, nle, nva, cha, chg, fph, cph, aib, and abu wherein amino acids written with an initial capital letter are L-amino acids and those written in all lower case letters are D-amino acids.

19. The compound according to claim 17 wherein the R<sup>2</sup> substituent is selected from the group consisting of a phenyl, 4-halophenyl, 4-(C<sub>1</sub>-C<sub>6</sub>-alkyl)phenyl and a C<sub>1</sub>-C<sub>6</sub> alkyl group.

20. The compound according to claim 17 wherein the R<sup>3</sup> substituent is selected from the group consisting of a hydrido, methyl, benzyl, 2-, 3- and 4-methylbenzyl, 2-, 3- and 4-fluorobenzyl, 2-, 3- and 4-chlorobenzyl, 2,4-, 3,4-, 3,5- and 2,6-difluorobenzyl, 4-(trifluoromethyl)benzyl, 4-(trifluoromethoxy)benzyl, 2-, 3-, and 4-methoxybenzyl, 3,5- and 3,4-dimethoxybenzyl, 2-, 3- and 4-nitrobenzyl, 2-, 3- and a 4-phenylbenzyl substituent.

21. A process for forming a 1,3-disubstituted-2,4,6-triazinetriene that comprises the steps of:

a) providing an amino acid reversibly bound to a solid phase, said amino acid having a free amino group and a side chain denominated  $R^1$ ;

b) reacting said free amine of the solid phase bound amino acid with an  $R^2$ -substituted isocyanate to form a solid phase-bound urea having  $R^1$  and  $R^2$  substituents;

c) reacting said solid phase-bound urea with chlorocarbonylisocyanate to form a 1,3-disubstituted-2,4,6-triazinetriene whose 1- and 3-substituents are  $R^1$  and  $R^2$ , respectively; and

d) cleaving said 1,3-disubstituted-2,4,6-triazinetriene from said solid support and recovering the cleaved material;

wherein  $R^1$  is selected from the group consisting of a hydrido,  $C_1$ - $C_{10}$  alkyl,  $C_1$ - $C_{10}$  substituted alkyl,  $C_7$ - $C_{16}$  phenylalkyl,  $C_7$ - $C_{16}$  substituted phenylalkyl, phenyl, substituted phenyl,  $C_3$ - $C_7$  cycloalkyl, and a  $C_3$ - $C_7$  substituted cycloalkyl group; and

$R^2$  is selected from the group consisting of a  $C_1$ - $C_{10}$  alkyl,  $C_1$ - $C_{10}$  substituted alkyl,  $C_7$ - $C_{16}$  phenylalkyl,  $C_7$ - $C_{16}$  substituted phenylalkyl, phenyl, substituted phenyl,  $C_3$ - $C_7$  cycloalkyl,  $C_3$ - $C_7$  substituted cycloalkyl, and a  $C_3$ - $C_7$  substituted cycloalkyl group.

22. The process according to claim 21 wherein  $R^1$  is selected from the group consisting of a hydrido, methyl, benzyl, 2-butyl, N,N-dimethylaminobutyl, N-methylaminobutyl, N-methyl-N-benzylaminobutyl, 2-methylpropyl, methylsulfinyl-ethyl,

methylthioethyl, N,N-dimethylaminoethyl, N,N-dimethylaminopropyl, N',N',N'-trimethylguanidinopropyl, N',N',N'-tribenzyl-guanidinopropyl, N',N'-dibenzylguanidinopropyl, N'-methylguanidinopropyl, hydroxymethyl, 1-hydroxyethyl, 2-propyl, N-methyl-3-indolylmethyl, 4-methoxybenzyl, 4-hydroxybenzyl, propyl, butyl, cyclohexylmethyl, phenyl, 2-naphthylmethyl, and a 4-imidazolylmethyl substituent.

23. The library according to claim 21 wherein R<sup>2</sup> is selected from the group consisting of a methyl, ethyl, isopropyl, n-propyl, butyl, t-butyl, cyclohexyl, n-octadecyl, phenyl, benzyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 3-chloro-4-methylphenyl, 3-bromo-4-methylphenyl, 3-fluorosulfonyl-phenyl, 3,4-(methylenedioxy)phenyl, 4-phenoxyphenyl, trans-2-phenylcyclopropyl, 4-toluenesulfonyl, 2-tolyl, 3-tolyl, 4-tolyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl,  $\alpha,\alpha,\alpha$ -trifluoro-2-tolyl,  $\alpha,\alpha,\alpha$ -trifluoro-3-tolyl,  $\alpha,\alpha,\alpha$ -trifluoro-4-tolyl, 2,5-dimethylphenyl, 3,4-dimethylphenyl and a 3,5-dimethylphenyl substituent.

24. The process according to claim 21 wherein the R<sup>1</sup> substituent is a side chain of an amino acid selected from the group consisting of Ala, Phe, Gly, Asp, Asn, Glu, Gln, His, Ile, Lys, Leu, Met, Arg, Nva, Ser, Thr, Val, Trp, Tyr, Nle, Cha, Chg, Fph, Cph, Nph, Aib, Abu, ala, phe, asp, asn, glu, gln, his, ile, lys, leu, met, arg, ser, thr, val, trp, tyr, nle, nva, cha, chg, fph, cph, aib, and abu wherein amino acids written with an initial

capital letter are L-amino acids and those written in all lower case letters are D-amino acids.

25. A process for preparing a 1,3,5-trisubstituted-2,4,6-triazinetri-  
one that comprises the step of alkylating the 1,3-disubstituted-2,4,6-triazinetri-  
one of claim (21) prior to step (d) using an  $R^3$  group-containing alkylating agent,

wherein  $R^3$  is selected from the group consisting of a hydrido,  $C_1$ - $C_{10}$  alkyl,  $C_1$ - $C_{10}$  substituted alkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_2$ - $C_{10}$  substituted alkenyl,  $C_2$ - $C_{10}$  alkynyl,  $C_2$ - $C_{10}$  substituted alkynyl,  $C_3$ - $C_7$  cycloalkyl,  $C_3$ - $C_7$  substituted cycloalkyl, phenyl,  $C_7$ - $C_{16}$  phenylalkyl,  $C_7$ - $C_{16}$  phenylalkenyl,  $C_7$ - $C_{16}$  phenylalkenyl and a  $C_7$ - $C_{16}$  substituted phenylalkenyl group.

26 The process according to claim 25 wherein  $R^3$  is selected from the group consisting of a hydrido,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl, benzyl, and a substituted benzyl substituent.

27. The process according to claim 25 wherein  $R^3$  is selected from the group consisting of a hydrido, methyl, benzyl, 2-, 3- and 4-methylbenzyl, 2-, 3- and 4-fluorobenzyl, 2-, 3- and 4-chlorobenzyl, 2,4-, 3,4-, 3,5- and 2,6-difluorobenzyl, 4-(trifluoromethyl)benzyl, 4-(trifluoromethoxy)benzyl, 2-, 3-, and 4-methoxybenzyl, 3,5- and 3,4-dimethoxybenzyl, 2-, 3- and 4-nitrobenzyl, 2-, 3- and a 4-phenylbenzyl substituent.